Advertisement Kite Pharma announces exclusive license with NIH for anti-CD19 CAR product candidate - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Kite Pharma announces exclusive license with NIH for anti-CD19 CAR product candidate

Kite Pharma has entered into an exclusive, worldwide license with the National Institutes of Health (NIH) for intellectual property related to a fully human anti-CD19 chimeric antigen receptor-based product candidate directed against B-cell malignancies.

The National Cancer Institute (NCI), with Dr. James N. Kochenderfer, M.D., an investigator in the Experimental Transplantation and Immunology Branch of the NCI, is currently conducting a Phase 1 clinical trial of the product candidate in patients with B-cell malignancies under an existing Cooperative Research and Development Agreement (CRADA) between Kite and the NCI.

Kite Pharma chairman, president, and CEO Arie Belldegrun said: "The expansion of our CAR-T pipeline to include a fully human anti-CD19 chimeric antigen receptor supports our effort to maximize the potential benefit of CAR-T therapies for patients with advanced B-cell malignancies.

"As the field of T-cell therapy continues its rapid advancement, we remain committed to collaborating with the world's most distinguished institutions and accessing the most significant enabling technologies to pioneer the next generation of T-cell therapies."